Ⓐ
PeptiBrief
Evidence Library
expert_review · 2019

International Union of Basic and Clinical Pharmacology. CVII. Structure and Pharmacology of the Apelin Receptor with a Recommendation that Elabela/Toddler Is a Second Endogenous Peptide Ligand

Read C|Fitzpatrick CM|Yang P|Kuc RE|Maguire JJ|Glen RC|Foster RE|Davenport AP · Pharmacological Reviews
strongDOI · 10.1124/pr.119.017533PMID · 31492821Verified
View source
Plain-English summary

The review establishes apelin and its active fragments as endogenous apelin-receptor ligands with important cardiovascular and fluid-balance biology.

Population
Apelin receptor literature
Intervention
Apelin isoforms, Elabela and synthetic receptor ligands
Outcomes measured
Receptor structure|Ligand pharmacology|Signalling|Physiology
Key findings
Provides an authoritative receptor and ligand framework.
Limitations
Expert narrative review|Therapeutic implications extend beyond direct clinical evidence
Risk of bias
Low-to-moderate for receptor classification and mechanism; higher for treatment claims.
Citation
Read C|Fitzpatrick CM|Yang P|Kuc RE|Maguire JJ|Glen RC|Foster RE|Davenport AP (2019). International Union of Basic and Clinical Pharmacology. CVII. Structure and Pharmacology of the Apelin Receptor with a Recommendation that Elabela/Toddler Is a Second Endogenous Peptide Ligand. Pharmacological Reviews. https://doi.org/10.1124/pr.119.017533
Linked peptides in the PeptiBrief database
ImportantPeptiBrief is an educational information platform. It does not diagnose, prescribe, sell peptides, recommend dosing, encourage self-experimentation or replace qualified medical care. Published scientific evidence is kept separate from community observations and uncertainty.